Ann Intern Med

1. WELLS CR, Pandey A, Moghadas SM, Fitzpatrick MC, et al
   Evaluation of Strategies for Transitioning to Annual SARS-CoV-2 Vaccination Campaigns in the United States.
   Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-2451.
   

   >> Share

   
   

   
   Antiviral Res

2. DE MEYER A, Meuleman P
   Preclinical animal models to evaluate therapeutic antiviral antibodies.
   Antiviral Res. 2024 Mar 26:105843. doi: 10.1016/j.antiviral.2024.105843.
   

   >> Share

   
   
3. PEREZ-VARGAS J, Lemieux G, Thompson CAH, Desilets A, et al
   Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
   Antiviral Res. 2024 Mar 26:105869. doi: 10.1016/j.antiviral.2024.105869.
   

   >> Share

   
   

   
   BMJ

4. MAHASE E
   Covid-19: Pfizer vaccine to be available privately at pharmacy chain Boots from April.
   BMJ. 2024;384:q762.
   

   >> Share

   
   
5. SHEPHERD A
   Covid remembered in NHS portraits.
   BMJ. 2024;384:q741.
   

   >> Share

   
   

   
   Clin Infect Dis

6. FUNK A, Florin TA, Kuppermann N, Finkelstein Y, et al
   Household Transmission Dynamics of Asymptomatic SARS-CoV-2-Infected Children: A Multinational, Controlled Case-Ascertained Prospective Study.
   Clin Infect Dis. 2024 Mar 26:ciae069. doi: 10.1093.
   

   >> Share

   
   

   
   Emerg Infect Dis

7. TANTIRAT P, Chantarawichian Y, Taweewigyakarn P, Kripattanapong S, et al
   Melioidosis in Patients with COVID-19 Exposed to Contaminated Tap Water, Thailand, 2021.
   Emerg Infect Dis. 2024;30:791-794.
   

   >> Share

   
   
8. SOLER-IBORTE E, Rivera-Izquierdo M, Valero-Ubierna C
   Opportunistic Elizabethkingia miricola Infections in Intensive Care Unit, Spain.
   Emerg Infect Dis. 2024;30:834-837.
   

   >> Share

   
   
9. SCHOLL M, Hohn C, Boucsein J, Moek F, et al
   Bus Riding as Amplification Mechanism for SARS-CoV-2 Transmission, Germany, 2021(1).
   Emerg Infect Dis. 2024;30:711-720.
   

   >> Share

   
   

   
   Int J Infect Dis

10. MINK S, Drexel H, Leiherer A, Frick M, et al
    Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: a prospective cohort study.
    Int J Infect Dis. 2024 Mar 21:107016. doi: 10.1016/j.ijid.2024.107016.
    

    >> Share

    
    
11. CHEUNG YYH, Lau EHY, Yin G, Lin Y, et al
    Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach.
    Int J Infect Dis. 2024 Mar 21:107012. doi: 10.1016/j.ijid.2024.107012.
    

    >> Share

    
    
12. WEIRAUCH T, Burger G, Cadar D, Gabriel M, et al
    Vaccine-derived Yellow Fever in an immunocompromised patient on anti-CD20-antibody therapy and its treatment with Sofosbuvir.
    Int J Infect Dis. 2024 Mar 21:107017. doi: 10.1016/j.ijid.2024.107017.
    

    >> Share

    
    

    
    Intensive Care Med

13. AZOULAY E, Resche-Rigon M, Pochard F, Souppart V, et al
    One-year outcomes in acute respiratory distress syndrome survivors: COVID-19 versus seasonal influenza or pneumonia.
    Intensive Care Med. 2024 Mar 27. doi: 10.1007/s00134-024-07396.
    

    >> Share

    
    

    
    J Infect

14. GAYLIS NB, Yang OO
    Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC) - The hunt for effective treatments.
    J Infect. 2024 Mar 24:106146. doi: 10.1016/j.jinf.2024.106146.
    

    >> Share

    
    

    
    J Med Virol

15. FARAONE JN, Wang X, Qu P, Zheng YM, et al
    Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
    J Med Virol. 2024;96:e29520.
    

    >> Share

    
    
16. ZHENG Z, Wu H, Sun X, Lu Y, et al
    Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS-CoV-2 vaccine and Ad5-nCoV booster in pediatric liver transplant recipients.
    J Med Virol. 2024;96:e29543.
    

    >> Share

    
    
17. OGUNJINMI OD, Abdullahi T, Somji RA, Bevan CL, et al
    The antiviral potential of the antiandrogen enzalutamide and the viral-androgen signaling interplay in seasonal coronaviruses.
    J Med Virol. 2024;96:e29540.
    

    >> Share

    
    

    
    JAMA

18. HARRIS E
    CDC Tracking BA.2.87.1, New Omicron Subvariant With Potential to Evade Immunity.
    JAMA. 2024;331:907.
    

    >> Share

    
    

    
    Lancet

19. SZANYI J, Howe S, Blakely T
    The importance of reporting accurate estimates of long COVID prevalence.
    Lancet. 2024;403:1136-1137.
    

    >> Share

    
    
20. WENHAM C, Stout L
    A legal mapping of 48 WHO member states' inclusion of public health emergency of international concern, pandemic, and health emergency terminology within national emergency legislation in responding to health emergencies.
    Lancet. 2024 Mar 22:S0140-6736(24)00156-9. doi: 10.1016/S0140-6736(24)00156.
    

    >> Share

    
    

    
    Lancet Infect Dis

21. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
    Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1.
    Lancet Infect Dis. 2024 Mar 21:S1473-3099(24)00155.
    

    >> Share

    
    
22. DE MENEZES NEVES PDM, Mohrbacher S, Lobato Vasques I, Barreira Cavalcante L, et al
    Renal infarction secondary to Aspergillus spp. embolism following COVID-19.
    Lancet Infect Dis. 2024;24:e266-e267.
    

    >> Share

    
    
23. DIXIT A, Bennett R, Ali K, Griffin C, et al
    Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00101.
    

    >> Share

    
    
24. LI SM, Zhu FC
    The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00157.
    

    >> Share

    
    
25. 
    Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
    

    >> Share

    
    

    
    MMWR Morb Mortal Wkly Rep

26. WILLIAMS PM, Pratt RH, Walker WL, Price SF, et al
    Tuberculosis - United States, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:265-270.
    

    >> Share

    
    
27. LINK-GELLES R, Rowley EAK, DeSilva MB, Dascomb K, et al
    Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged >/=18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:271-276.
    

    >> Share

    
    

    
    Science

28. TAN B, Zhang X, Ansari A, Jadhav P, et al
    Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model.
    Science. 2024;383:1434-1440.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share